Reata collaborates with leading researchers in our key areas of interest. We focus on building effective partnerships with our academic collaborators to assure that we develop the full potential of our drug candidates.
The biology underlying Reata’s AIMs is an important emerging area of scientific research. Reata has established many collaborations with leaders in this field who are actively publishing on Reata’s drugs and their pharmacology. Some of our most active collaborators in this field include:
 |
Michael Andreeff, M.D., Ph.D. conducted seminal early work on the AIMs in cancer and recently demonstrated their effects on the JAK/STAT pathway. He is a Professor and Section Chief of Molecular Hematology and Therapy at The University of Texas M.D. Anderson Cancer Center. |
|
Donald Kufe, M.D. has done extensive research on the pharmacology of the AIMs, including identification of binding sites on IKK-β and the JAK/STAT pathway. He is a Professor of Medicine at Harvard Medical School and Leader, Translational Pharmacology and Early Therapeutic Trials Program at the Dana-Farber Cancer Institute. He has previously served as chief of the Division of Cancer Pharmacology, deputy director of the Dana-Farber Cancer Center, director of the Harvard Phase I Oncology Group, and leader of the Experimental Therapeutics Program. Recently, Dr. Kufe served as the editor of Cancer Medicine, a reference manual published by the American Association of Cancer Research. |
|
Michael Sporn, M.D. is the inventor of RTA 402 and related AIMs and continues to make important contributions to understanding their unique pharmacology. Dr. Sporn is the author of over 20 publications in Nature and currently serves as a Professor of Pharmacology and Medicine at Dartmouth Medical School. He is widely known as the “father of chemoprevention” for his pioneering work in this field. |
Click Here for a more comprehensive list of researchers working on the AIMs and their relevant publications.
[Return to Top]
Reata maintains an active, ongoing collaboration with Dr. Philip J. Thomas, one of our Founding Scientists and a pioneer in the field of protein misfolding. Dr. Thomas published a seminal paper demonstrating that protein misfolding led to disease (cystic fibrosis) and remains an internationally recognized expert in this field. His academic appointment is as a Professor of Physiology at UT Southwestern Medical Center in Dallas, TX.
[Return to Top]
Dr. Thomas C. Südhof, M.D., a Reata Founding Scientist, has published extensively in the fields of neurotransmitter release and synaptic development. Dr. Südhof serves as a Professor of Molecular Genetics and the Director of the Center for Basic Neuroscience at UT Southwestern; he is a member of both the National Academy of Sciences and the Institute of Medicine; he has also been a Howard Hughes Medical Institute Investigator since 1986.
[Return to Top]
Reata maintains active collaborations with a number of researchers with deep expertise in cancer biology, chemistry, and drug development.
|
Timothy Madden, Pharm.D. is an expert in cancer drug pharmacology and serves as Co-Director of the Pharmaceutical Development Center, Cancer Therapeutics Discovery Program, at The University of Texas M.D. Anderson Cancer Center. He is also an Associate Professor of Pharmacology at M.D. Anderson and serves as their Director of Pharmaceutical Research in the Division of Pharmacy. |
|
Waldemar Priebe, Ph.D. is the inventor of berubicin (RTA 744) and an expert in the use of chemical libraries to design novel compounds that address deficiencies of existing cancer therapies. Dr. Priebe is a Professor of Chemistry and of Medicinal Chemistry in the the Department of Experimental Therapeutics at The University of Texas M.D. Anderson Cancer Center and a Founding Scientist of Reata. |
|
Jerry Shay, Ph.D. is well known in the scientific community for his contributions to research in cellular aging and telomeres. In addition to 18 issued patents on his age and cancer-related research, Dr. Shay has published over 250 scientific articles, written 50 book chapters, and edited 10 books. He serves as a Professor and Vice Chairman of the Department of Cell Biology at UT Southwestern and holds the Southland Corporation Distinguished Chair in Geriatrics Research. |
[Return to Top]
Several Reata products are derived from natural products. We maintain a network of collaborators with particular expertise in this area.
|
Jef Karel De Brabander, Ph.D. is an expert in the synthesis and biological evaluation of complex biologically active compounds, and medicinal/pharmaceutical chemistry. He is a Professor in the Department of Biochemistry at UT Southwestern and a Founding Scientist of Reata. |
|
Peter Northcote, Ph.D. is an expert in the isolation and structural elucidation of novel compounds from marine organisms, scale up of natural products isolation and NMR spectroscopy. He is an Associate Professor of Chemistry in the School of Chemical and Physical Sciences of Victoria University of Wellington, New Zealand. |
[Return to Top] |
